Accordingly, in this study we investigated the hypothesis that dystrophin mutations in DMD lead to cardiomyopathy-causing bioenergetic/metabolic impairments, which could be therapeutically targeted to improve cardiac function. Here, DMD is linked to cardiomyopathy.